{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:38:44Z","timestamp":1793835524453,"version":"4.6.1"},"reference-count":2,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing and monitoring recommendations. The previous 2009 vancomycin consensus guidelines recommend trough monitoring as a surrogate marker for the target area under the curve over 24 hours to minimum inhibitory concentration (AUC\/MIC). However, recent data suggest that trough monitoring is associated with higher nephrotoxicity. This document is an executive summary of the new vancomycin consensus guidelines for vancomycin dosing and monitoring. It was developed by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. These consensus guidelines recommend an AUC\/MIC ratio of 400\u2013600 mg*hour\/L (assuming a broth microdilution MIC of 1 mg\/L) to achieve clinical efficacy and ensure safety for patients being treated for serious methicillin-resistant Staphylococcus aureus infections.<\/jats:p>","DOI":"10.1093\/cid\/ciaa303","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:02:55Z","timestamp":1594641775000},"page":"1361-1364","source":"Crossref","is-referenced-by-count":259,"title":["Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists"],"prefix":"10.1093","volume":"71","author":[{"given":"Michael J","family":"Rybak","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"},{"name":"Detroit Receiving Hospital, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P","family":"Levine","sequence":"additional","affiliation":[{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"},{"name":"Detroit Receiving Hospital, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California, USA"},{"name":"Rady Children\u2019s Hospital San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Mueller","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath P","family":"Pai","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Wong-Beringer","sequence":"additional","affiliation":[{"name":"University of Southern California School of Pharmacy, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Rotschafer","sequence":"additional","affiliation":[{"name":"University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Rodvold","sequence":"additional","affiliation":[{"name":"University of Illinois College of Pharmacy, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly D","family":"Maples","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences College of Pharmacy and Arkansas Children\u2019s Hospital, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lomaestro","sequence":"additional","affiliation":[{"name":"Albany Medical Center Hospital, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"2020091210442191500_CIT0001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society by America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"key":"2020091210442191500_CIT0002","first-page":"1193","article-title":"The periodic health examination. Canadian Task Force on the Periodic Health Examination","volume":"121","year":"1979","journal-title":"Can Med Assoc J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa303\/33659850\/ciaa303.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/6\/1361\/33738619\/ciaa303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/6\/1361\/33738619\/ciaa303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T10:45:17Z","timestamp":1599907517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/6\/1361\/5870833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":2,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,7,13]]},"published-print":{"date-parts":[[2020,9,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa303","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,15]]},"published":{"date-parts":[[2020,7,13]]}}}